OVERVIEW

Leveraging Relevant Biological Factors in the Treatment of Early HER2-Positive Breast Cancer: Closing the Quality Chasm is organized by Med Learning Group.

Release Date: August 6, 2018
Expiration Date: August 6, 2019

Target Audience:
This CME initiative is designed to meet the educational needs of medical oncologists, gynecologic oncologists, gynecologic surgeons, oncology nurses, and other healthcare providers involved in the treatment of patients with early breast cancer.

Accreditation:
Med Learning Group designates this enduring activity for a maximum of 2.5 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer.
Credits: 2.5 ANCC Contact Hours

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.5 contact hours of continuing nursing education of RNs and APNs.

Program Overview:
This online activity is focused on the care of patients with early HER2-positive breast cancer.

Learning Objectives:
After completing the CME activity, learners should be better able to:
• Describe the biological markers that characterize the pathologic assessment of HER2-positive breast cancer
• Explain currently available adjuvant treatment regimens for patients with HER2-positive breast cancer
• Review the emerging clinical trial data for dual anti-HER2 strategies with chemotherapy in the adjuvant setting
• Discuss how quality measures may drive practice change to optimize care for patients with HER2-positive advanced breast cancer